Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Xlife Sciences Ltd. ( (CH:XLS) ) has provided an announcement.
VERAXA Biotech AG, a portfolio company of Xlife Sciences AG, has reached a significant milestone by submitting a prospectus for a NASDAQ listing, marking progress towards a merger with Voyager Acquisition Corp. This move is expected to enhance VERAXA’s market position and valuation, potentially reaching a market capitalization of USD 1.64 billion. The transaction is anticipated to provide VERAXA with substantial cash access and reflects the company’s strategic focus on becoming a global player in oncology therapies. The merger is expected to be completed in the fourth quarter of 2025, pending shareholder approval.
More about Xlife Sciences Ltd.
Xlife Sciences AG is a Swiss company focused on the value development and commercialization of research projects in the life sciences sector. It holds a 19% stake in VERAXA Biotech AG, which is involved in developing oncology therapies.
Average Trading Volume: 3,426
Current Market Cap: CHF109.7M
Learn more about XLS stock on TipRanks’ Stock Analysis page.